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Intracranial Injection of AAV Expressing NEP but Not IDE
Reduces Amyloid Pathology in APP+PS1 Transgenic Mice
Nikisha Carty1.¤, Kevin R. Nash1., Milene Brownlow1, Dana Cruite1, Donna Wilcock2, MajLinda B. Selenica3, Daniel C. Lee3, Marcia N. Gordon1, Dave Morgan1*
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Pharmaceutical Sciences, University of South Florida College of Pharmacy, Byrd Alzheimer Institute, Tampa, Florida, United States of America

Abstract
The accumulation of b-amyloid peptides in the brain has been recognized as an essential factor in Alzheimer’s disease
pathology. Several proteases, including Neprilysin (NEP), endothelin converting enzyme (ECE), and insulin degrading
enzyme (IDE), have been shown to cleave b-amyloid peptides (Ab). We have previously reported reductions in amyloid in
APP+PS1 mice with increased expression of ECE. In this study we compared the vector-induced increased expression of NEP
and IDE. We used recombinant adeno-associated viral vectors expressing either native forms of NEP (NEP-n) or IDE (IDE-n),
or engineered secreted forms of NEP (NEP-s) or IDE (IDE-s). In a six-week study, immunohistochemistry staining for total Ab
was significantly decreased in animals receiving the NEP-n and NEP-s but not for IDE-n or IDE-s in either the hippocampus or
cortex. Congo red staining followed a similar trend revealing significant decreases in the hippocampus and the cortex for
NEP-n and NEP-s treatment groups. Our results indicate that while rAAV-IDE does not have the same therapeutic potential
as rAAV-NEP, rAAV-NEP-s and NEP-n are effective at reducing amyloid loads, and both of these vectors continue to have
significant effects nine months post-injection. As such, they may be considered reasonable candidates for gene therapy
trials in AD.
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glycoprotein found in both pre- and post-synaptic membranes in
the nigrostriatal region and hippocampus, and is involved in the
degradation of signaling peptides in the synaptic cleft. ECE-1 is
also a transmembrane protein with an extracellular catalytic site,
and is found in neurons, glia, and endothelial cells [8]. All three
enzymes have been shown to degrade Ab both in vitro and in vivo
[5,9,10,11,12,13].
We have previously reported on the successful over-expression
of ECE-1, and the resultant reduction in Ab load in transgenic
mice due to intracranial injection of recombinant adeno-associated
viral vectors (rAAV) containing the ECE-1 gene [8]. Our goal in
the present study was to further explore the effects of Ab degrading
enzyme up-regulation in the brains of transgenic mice. To do this,
we used rAAV vector- mediated delivery of NEP and IDE cDNA
into the hippocampus and frontal cortex of APP+PS1 mice. We
chose rAAV vectors because they are capable of inducing longterm transgene expression in non-dividing cells without provoking
a significant inflammatory response [14]. Two forms of each
protease gene were used, one that codes for the native protein
(NEP-n and IDE-n), and one that codes for a truncated protein
that is secreted into the extracellular space (NEP-s and IDE-s). We
found that only mice injected with rAAV- NEP-s or NEP-n
constructs showed a significant reduction in Ab levels as compared

Introduction
The amyloid cascade hypothesis of Alzheimer’s disease (AD)
proposes that the neurodegeneration and cognitive dysfunction
characteristic of Alzheimer’s disease (AD) stem from the abnormal
accumulation of amyloid-b (Ab) within the brain [1]. Ab is
normally cleared from the brain via several mechanisms, which
can be broadly divided into transport out of the CNS or enzymatic
degradation of the peptide [2]. Accumulation of Ab can therefore
occur when there is an imbalance between the normal rates of
production and clearance of this protein.
While excessive production of Ab due to autosomal dominant
mutations in the APP, presenilin-1 (PS1), or presenilin-2 (PS2)
genes is the mechanism causing early onset, familial AD, it has
been suggested that insufficient clearance of Ab, potentially by
certain Ab-degrading enzymes may be responsible for accumulation of Ab in cases of late onset, sporadic AD [3,4,5,6]. Three of
these enzymes are insulin-degrading enzyme (IDE), neprilysin
(NEP), and endothelin-converting enzyme-1 (ECE-1), all of which
are zinc metalloproteases normally expressed within the brain.
IDE is a dimer predominantly found in the cytosol of neurons, but
also exists in peroxisomes, within the plasma membrane, and is
secreted from microglial cells [7]. NEP is a transmembrane
PLOS ONE | www.plosone.org
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secreted form of NEP. Mice were sacrificed at 7.5 months old, 6
weeks after the injection.
In study 2, 6 month old APP+PS1 mice received unilateral,
intracranial injections of rAAV vector expressing GFP (control) in
the right anterior cortex and right hippocampus (coordinates as
above; n = 8). The second (n = 8) and third (n = 8) groups received
identically placed injections of either rAAV-IDE-n, the native
form of the IDE gene, or rAAV-IDE-s, the secreted form of the
gene. The mice were euthanized at 7.5 months old, or 6 weeks
post injection. In study 3, 7 month old APP+PS1 mice were split
into four groups: the first group (n = 9) was untreated. The second
group (n = 7) received bilateral, intracranial injections of rAAV
vector expressing NEP-m in both the hippocampus and anterior
cortex for a total of four injections. The third (n = 4) and fourth
(n = 6) groups received injections of rAAV-NEP-n or rAAV-NEPs, respectively. Animals were euthanized at 16 months of age, or 9
months post injection.

to controls. This was observed in both the frontal cortex and in the
hippocampus, and in both young (7.5 month old) and old (16
month old) mice. Neither IDE-s nor IDE-n caused a significant
reduction in Ab levels in either the hippocampus or anterior
cortex.

Materials and Methods
Ethics Statement
All animal testing procedures were approved by the Institutional
Animal Care and Use Committee of the University of South
Florida and followed the NIH guidelines for the care and use of
laboratory animals (Approval ID number A4100-01).

Generation of NEP and IDE Gene Constructs & rAAV
Vector Production and Purification
For the NEP-n and IDE-n constructs, the NEP gene (GI:
4503442) and the IDE gene (GI: 4826769) were cloned from a
human GenePool cDNA library (Invitrogen) using PCR. The NEP
constructs were previously described in Lebson et al (2010) [15].
Briefly, the secreted NEP (NEP-s) included amino acids 232–2313
and the GDNF signal sequence for secretion. The inactive NEP
(NEP-m) contained the E585V mutation. All NEP constructs had
a C-terminal haemagglutinin tag. For the IDE gene, the primers
used
were
GAGCTCGAGACCGGTCCACCATGCGGTACCGGCTAGCGTGGCTTCTGC and GAGATCGATTCAGAGCTTAGCAGCCATGAAGTTAATATGTGG. As with
NEP, a haemagglutinin (HA) tag was added to the C-terminus of
IDE to distinguish the transduced gene from the endogenous IDE.
The secreted/truncated form of IDE (124–3053 bp) was generated
by PCR and a signal sequence (MALLVHFLPLLALLALWEPKPTQAFV) was added to the N-terminus. The human
genes were examined because the human APP transgene is
expressed in these mice (and thus the Ab) and we wanted to
examine if these would be useful proteases for translation into
human use. The NEP-s and IDE-s were designed with the belief
that a secreted form would allow for diffusion and therefore
achieve a larger area of protease activity than the native
membrane bound. Production and purification of rAAV vectors
was performed according to the methods of Zolotukhin et al. [16].
rAAV serotype 5 was used for study 1, and rAAV serotype 9 was
used for studies 2 and 3. Infectious rAAV particles were expressed
as vector genomes (vg)/mL. Vector genomes were quantitated
using a dot blot protocol [16].

Immunohistochemistry
The methods of brain fixation, cryoprotection, and sectioning
are described in Carty et al [18]. For all three studies, free-floating
immunochemical and histological analysis was performed on six to
eight sections from each mouse brain, with the sections spanning
the injection site as described in Wilcock et al [19]. IDE and NEP
expression was assessed using anti-HA biotinylated rabbit polyclonal antibody (Roche, Indianapolis, IN). For all studies, Ab was
assessed using a rabbit primary anti-Ab antibody (Gift from Dr. P
Gottschal). The epitope for this antibody is N-terminal, and the
antiserum does not discriminate Abx240 vs. Abx242. In study 3, the
level of microglial activation was also assessed by using rabbit
primary anti-CD45 antibodies (ThermoScientific, Rockford IL.)
and anti-CD68 antibodies (AbD Serotec). Congo red staining to
assess compact congophilic plaque load was performed as
described in Carty et al [8].

Imaging and Data Analysis
Stained sections were imaged using an Evolution MP digital
camera mounted on an Olympus BX51 microscope at 1006 final
magnification (106objective), except for the congo red staining for
study 2. The sampling procedure, segmentation of positive staining
and quantification of percent area of positive stain was performed
as described in Carty et al [18]. The Congo red stained sections
from study 2 were imaged using a Zeiss Mirax Scan 150
microscope, and identification of positive staining product and
percent area of positive stain was performed using Image Analysis
software (created by Andrew Lesniak, Zeiss), also as described in
Carty et al [18]). Within each study and brain region, data were
analyzed using one-way ANOVA statistical analysis followed by
Fisher’s LSD test for individual means differences, as recommended by the computer software program StatViewH version
5.0.1 (SAS Institute, Raleigh, NC). All animals in each group
outlined above were used in data analysis.

Study Design
Transgenic APP+PS1 mice were used for 3 independent
experiments. These mice were obtained from a breeding colony
at the University of South Florida, and have been maintained for
.15 years. This line has been shown to have a selective increase in
the level of Ab42 as opposed to Ab40 [17] and to develop
extracellular Ab deposits, which increase in number, size and
density with aging (Gordon et al, 2002). Mice were kept under
standard vivarium conditions. Intracranial injections, mice handling, and euthanasia were performed as described in Carty et al
[18].
In study 1, 6 month old APP+PS1 mice were randomly assigned
to three groups. The first group received unilateral, intracranial
injections of rAAV vector expressing NEP-m (n = 15), an inactive
form of NEP, in both the right anterior cortex (AP 2.0, Lat 2.0,
DV 23.0) and right hippocampus (AP 2.7, Lat 22.7, DV 23.0).
The second group received identically- placed injections of rAAVNEP-n (n = 18), the native form of NEP, and the third group
received identically placed injections of rAAV-NEP-s (n = 17), the
PLOS ONE | www.plosone.org

Enzyme Activity Assay
Activity of the IDE constructs was assessed using the
InnozymeTM Insulysin/IDE Immunocapture kit (Calbiochem).
HEK293 cells were transfected with IDE-n, IDE-s, and GFP
plasmids using the LipofectamineTM 2000 by Invitrogen protocol.
Cells were harvested 48 hours later by centrifugation (5 min,
1,5006g). The cell pellets were re-suspended with 250 mL of lysis
buffer (20 mM HEPES, 5 mM KCl, 1.5 mM MgCl2, pH 7.5), and
subjected to three freeze-thaw cycles to obtain the cell lysates. The
protein concentration of each cell lysate was determined using a
BCA assay (Per Pierce Protocol). Western blot was performed to
2
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confirm IDE-n and IDE-s protein expression (using an anti-HA
antibody), and enzyme activity was measured. Fluorescence was
measured using a BioTek spectrofluorometer plate reader at 37uC.
Enzyme activity values are expressed as relative fluorescent units
(RFU)/min/mg of lysate.

Results
Study 1
In this experiment, we examined the over-expression of the
three rAAV vectors designed to express different versions of the
human NEP gene that we described previously [15]. These
included the native, membrane bound form of the enzyme (NEPn), a secreted form of the enzyme (NEP-s), and an enzymatically
deficient mutant enzyme (NEP-m). Enzyme activity was previously
reported for the membrane and soluble NEPs [15]. The NEP-s
enzyme was successfully secreted from cells, as evidenced by its
detection in the cell media fractions from NEP-s transfected
HEK293 cells (results not shown). The transgene expression of
NEP was assessed six weeks after unilateral, intracranial injections
into the right hippocampus and anterior cortex of APP+PS1 mice
by immunostaining of mouse brain tissue with an anti-haemagglutinin (HA) tag antibody (Fig. 1).
In the ipsilateral hippocampus, anti-HA staining revealed NEP
expression in all animals for NEP-n, NEP-m and NEP-s, with
widespread gene expression throughout the entire hippocampus.
NEP-n was detected in CA4 neurons in the hilus, in CA2 and CA3
neurons of the pyramidal cell layer of the hippocampus, and in the
entorhinal cortex (Fig. 1a). Interestingly, it appears that the cell
bodies in the dentate granule cell layer were not stained as
intensely as the corresponding neuropil, suggesting some synaptic
localization of the transfected protein. NEP-s was detected in cell
bodies of CA4 neurons in the hilus, CA3 neurons, and in a small
number of cells in the molecular layers of hippocampus (Fig. 1c).
NEP-s expression had a more limited area of distribution, and
staining was noticeably less intense than that of both NEP-n and
NEP-m. It is uncertain the degree to which this reflects reduced
expression, or diffusion of the soluble enzyme in vivo or during
tissue processing. The expression pattern of NEP-m was very
similar to that of NEP-n, with expression throughout the
hippocampus, including the dentate gyrus and all CA regions
(Fig. 1b). There was no noticeable anti-HA staining in the
uninjected, contralateral hippocampus (Fig. 1d).
In the ipsilateral cortex, anti-HA staining again showed that
NEP-s expression was both less intense, and limited in distribution
compared to both NEP-m and NEP-n (Fig. 1). NEP-n and NEP-m
expression patterns were again similar, with the greatest intensity
of staining in the anterior cortex (Fig. 1e, f), and lighter staining in
the striatum and corpus callosum. As in the hippocampus, NEP-n
expression was largely confined to the neuropil, with less staining
of the neuronal somata. NEP-s staining, though, was seen mostly
in the somatic area of neurons, possibly due to packaging of the
enzyme into vesicular compartments in preparation for secretion
(Fig. 1g). Last, when comparing the intensity of HA immunohistochemical staining in anterior cortex to that in the hippocampus
for each enzyme, the staining in the anterior cortex always
appeared less intense, possibly indicating a lower level of NEP
gene expression in this region. Again, there was no noticeable antiHA staining in the uninjected, contralateral anterior cortex
(Fig. 1h).
Next, we investigated Ab levels of APP+PS1 mice following the
NEP administration. Animals injected with the control rAAVNEP-m showed both darkly stained compact plaques and more
lightly stained, more diffuse plaques, which were distributed
PLOS ONE | www.plosone.org

Figure 1. Study 1: Distribution of HA expression in the
hippocampus (A–D) and frontal cortex (E–H) following intracranial administration of rAAV vectors, detected using an antiHA antibody. Panels A & E show NEP-n treated animals; panels B & F
show NEP-m treated animals; panels C & G show NEP-s treated animals.
Panels D & H show no positive staining in the contralateral uninjected
left hippocampus and left anterior cortex, respectively. Scale
bar = 120 mm.
doi:10.1371/journal.pone.0059626.g001

throughout the anterior cortex (Fig. 2d) as well as in the
hippocampus (Fig. 2A). The staining was most concentrated in
the molecular layers of the dentate gyrus and the CA1 region
surrounding the hippocampal fissure. This staining pattern was
comparable to that in age matched, untreated APP+PS1
transgenic mice [20]. Compared to mice injected with rAAVNEP-m, mice injected with either rAAV-NEP-n or rAAV-NEP-s
showed significantly less Ab staining in both the hippocampus and
anterior cortex (Fig. 2). ANOVA analysis of Ab burden in NEP-n
mice revealed a significant decrease of 78% in the anterior cortex
as compared with NEP-m mice, and a significant decrease of 65%
in the hippocampus as compared to NEP-m mice (Fig. 2g).
Decreases in Ab were also observed in mice that received rAAVNEP-s. ANOVA analysis of Ab in NEP-s mice showed a
significant decrease of 60% in the anterior cortex and 56% in
the hippocampus as compared with NEP-m mice (Fig. 2g). These
3
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positive congophilic staining patterns throughout the cortex and
hippocampus (Fig. 3a, 3d), in a pattern comparable to that of age
matched, untreated APP+PS1 transgenic mice (Gordon et al,
2002). Compared to mice treated with NEP-m, mice treated with
NEP-n and NEP-s showed visibly less positive congophilic staining,
especially in the hippocampus (Fig. 3). ANOVA analysis of
congophilic load revealed that animals receiving rAAV-NEP-n
showed significant reductions of 56% in both the ipsilateral
hippocampus and anterior cortex as compared to mice treated
with NEP-m (Fig. 3g). Mice receiving rAAV-NEP-s also had
significant decreases in the compact plaque load in both the
ipsilateral hippocampus (51%) and anterior cortex (57%) compared to NEP-m mice (Fig. 3g). In the contralateral hemisphere, a
significant decrease as compared to NEP-m mice was only

reductions in Ab staining were not limited to the areas ipsilateral
to the injection sites – reductions were also noted in the
contralateral anterior cortex and hippocampus. Quantification
and ANOVA analysis of Ab in NEP-n mice showed a significant
reduction of 56% in the contralateral anterior cortex, and a
reduction of 36% in the contralateral hippocampus (Fig. 2h).
Similarly, analysis of Ab in NEP-s mice showed significant
decreases of 53% and 44% in the contralateral anterior cortex
and contralateral hippocampus, respectively (Fig. 2h). We did not
observe significant neuron staining for NEP on the contralateral
side, which may suggest that we are seeing axonal transport of
NEP rather than retrograde transport of the injected virus.
Histochemical analysis of congophilic amyloid plaques revealed
that animals injected with the control rAAV-NEP-m showed

Figure 2. Study 1: Ab immunostaining is observed in mice throughout both the ipsilateral hippocampus (A, B and C) and ipsilateral
anterior cortex (D, E and F). Ab staining in the hippocampus of animals that received intracranial injections of rAAV- NEP-n (B) or NEP-s (C) is
reduced compared to staining in those animals that received injections of control vector rAAV- NEP-m (A). Ab staining in the anterior cortex of mice
that received intracranial injections of rAAV- NEP-s (F) or NEP-n (E) is also reduced compared to staining in mice that received control vector rAAVNEP-m (D). Scale bar = 120 mm. Quantification of percent area of positive total Ab staining is shown in the hemisphere ipsilateral to injection sites (G)
and in the hemisphere contralateral to injection sites (H). NEP-n (n = 18), NEP-m (n = 15), NEP-s (n = 17). The (*) indicates significance compared to
NEP-m with p,0.05; the (**) indicate significance compared to NEP-m with p,.001.
doi:10.1371/journal.pone.0059626.g002

PLOS ONE | www.plosone.org
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observed in the hippocampus of animals treated with NEP-s (49%;
Fig. 3h). NEP-n treated mice showed a trend towards decreased
congophilic staining in the contralateral hippocampus, but no
significant difference as compared to NEP-m mice was observed.
There were no significant decreases in congophilic staining in the
contralateral anterior cortex of either NEP-n or NEP-s treated
mice (Fig. 3h).
These results with NEP are similar to those observed previously
with rAAV delivered ECE [8]. However it is worth noting that a
construct of a soluble secreted ECE did not seem to yield an active
enzyme, as we did not observe a decrease in amyloid loads in
APP+PS1 mice as we do with the secreted NEP (data not shown).

Study 2
In study 2, two rAAV vectors expressing different versions of the
human IDE gene were developed in a manner similar to that used
in study 1. The two versions included the native, membrane
bound enzyme (IDE-n), and a secreted form of the enzyme (IDEs). As a control, this study used a rAAV vector expressing GFP. All
gene sequences were tagged with a HA peptide sequence for
detection within the brain and discrimination from endogenous
IDE.
Like the NEP constructs, the IDE constructs were tested prior to
virus production. Constructs were transfected into HEK293 cells
to evaluate the expression and the effectiveness of the signaling
peptide. IDE-n transfected cell lysate, but not media, was positive

Figure 3. Study 1: Congophilic staining is observed in mice throughout both ipsilateral hippocampus (A, B and C) and ipsilateral
anterior cortex (D, E and F). Congophilic staining in the hippocampus of animals that received intracranial injections of rAAV- NEP-n (B) or NEP-s
(C) is reduced compared to staining in those animals that received injections of control vector rAAV- NEP-m (A). Congophilic staining in the anterior
cortex of mice that received intracranial injections of rAAV- NEP-s (F) or NEP-n (E) is also reduced compared to staining in mice that received control
vector rAAV- NEP-m (D). Scale bar = 120 mm. Quantification of percent area of positive total Congophilic staining is shown in G (hemisphere ipsilateral
to injection sites) and H (hemisphere contralateral to injection sites). NEP-n (n = 18), NEP-m (n = 15), NEP-s (n = 17). The (*) indicates significance
compared to NEP-m with p,0.05.
doi:10.1371/journal.pone.0059626.g003

PLOS ONE | www.plosone.org
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Congophilic plaque load was also analyzed nine months after
bilateral, intracranial injection of rAAV-NEP-m, rAAV-NEP-n, or
rAAV-NEP-s. The staining pattern in the NEP-m mice was
comparable to that in age matched, untreated APP+PS1
transgenic mice, and no significant differences were found in the
level of congophilic staining between these two groups. Mice
treated with NEP-n showed visibly less positive congophilic
staining than mice treated with NEP-m in both the anterior
cortex and hippocampus (Fig. 7b, 7e). ANOVA analysis of
congophilic staining revealed that NEP-n treated mice experienced a significant reduction of 76% in the hippocampus, and a
significant reduction of 80% in the anterior cortex compared to
NEP-m treated mice (Fig. 7g, 7h). Similarly, mice injected with
NEP-s showed decreases in congophilic staining in both the
hippocampus and anterior cortex. By ANOVA analysis of total
congophilic staining, NEP-s mice had a non-significant decrease of
48% in the hippocampus, and a significant decrease of 67% in the
anterior cortex as compared to NEP-m mice (Fig. 7g, 7h).
The relationship between NEP over-expression via intracranial
injection of rAAV-NEP-n, rAAV-NEP-s, and rAAV-NEP-m,
clearance of Ab plaques, and immune system activation was also
investigated. This was done by immunohistochemical analysis
using CD45 and CD68, markers of microglial cell activation.
Animals treated with rAAV-NEP-m showed both CD45 and
CD68 staining throughout the hippocampus (Fig. 8a–f) and
anterior cortex (not shown), in a pattern comparable to untreated
transgenic mice of this age in other studies (Gordon et al, 2002).
Clusters of microglia expressing these activation markers are
intensely stained at the perimeter of amyloid deposits. When the
fractional area is measured, there is no significant change in these
markers in both the NEP-n and NEP-s expressing mice. However,
differences were observed when the ratio of microglial staining:Congo red staining was calculated for the hippocampus (Fig. 8g,
8h) and the anterior cortex (data not shown). Mice treated with
rAAV-NEP-n showed a significant increase (84%) in the
CD68:Congo red ratio, and a significant 4- fold increase in the
CD45:Congo red ratio in the hippocampus, compared to mice
treated with rAAV-NEP-m (Fig. 8g, 8h). However, rAAV-NEP-n
was not significantly different from the control in the anterior
cortex (data not shown). Mice treated with rAAV-NEP-s trended
toward increases in the CD68:Congo and CD45:Congo ratios in
the hippocampus, but these were not significant (Fig. 8g, 8h). In
the anterior cortex, rAAV-NEP-s showed a significant increase
(1.5 fold; P,0.01) in the CD68:Congo red ratio but no difference
in the CD45:congo red ratio compared to controls.

for IDE protein expression by Western analysis. However, IDE-s
transfected cell lysate and media was positive for IDE protein,
showing effective secretion of the IDE protein due to the signaling
peptide (data not shown). The cell lysate was also used to examine
IDE activity. The IDE specific activity of IDE-n transfected cells
was 3029 RFU/min/mg, that of IDE-s transfected cells was
166 RFU/min/mg, and that of GFP- transfected cells was
2.75 RFU/min/mg. Western analysis showed similar levels of
recombinant protease expression for both forms, which indicates
that the secreted form, although active, has less activity than the
native IDE. This suggests that unlike NEP-s, which retained a
similar activity to the native NEP [15], IDE-s may be a less
effective construct.
Sections were stained for HA after administration of IDE
constructs. Similar to what was observed with NEP-s in study 1,
IDE expression was revealed in both IDE-n and IDE-s treated
mice in the ipsilateral hippocampus and cortex. The pattern of
expression of IDE-n was similar to that observed with NEP-n, as
described above (data not shown). IDE-s expression had a more
limited area of distribution, and staining was less intense than that
of IDE-n. In the transgenic control mice and in the hippocampus
and anterior cortex contralateral to the injection sites in treated
mice, there was no noticeable anti-HA staining.
Next, the effect of IDE over-expression on amyloid load in
APP+PS1 transgenic mice was evaluated. In the ipsilateral
hippocampus, Ab staining patterns were very similar between
the three groups (IDE-n, IDE-s, and GFP), showing comparable
amounts of both darkly-stained compact plaques and lighter, more
diffuse plaques (Fig. 4a–c). ANOVA analysis confirmed this,
revealing no significant differences in Ab load between the GFP,
IDE-n, and IDE-s groups (Fig. 4g). In the ipsilateral anterior
cortex, Ab staining patterns were again similar between the groups
(Fig. 4d–f). ANOVA analysis confirmed that there was no
significant difference in total Ab load between the IDE-n, IDE-s,
and GFP groups (Fig. 4h). Similarly, Congo red staining patterns
were very similar between all groups (Fig. 5), and ANOVA
analysis showed no significant differences in congophilic load
between the GFP, IDE-n, and IDE-s groups in either the
ipsilateral hippocampus (Fig. 5g) or anterior cortex (Fig. 5h).

Study 3
Study 3 was designed to examine a long-term over-expression of
Ab-degrading proteases. Since the IDE vectors were not successful
in reducing Ab in the short term, we focused our examination on
the NEP expression vectors. Unlike the previous two studies,
transgene expression was assessed nine months after bilateral,
intracranial injections of the vectors into the hippocampus and
anterior cortex of APP+PS1 mice.
Similar to study 1, animals injected with the control rAAVNEP-m showed both darkly stained compact plaques and more
lightly stained Ab distributed throughout the anterior cortex
(Fig. 6d) and hippocampus (Fig. 6a). The staining pattern in the
NEP-m mice was comparable to that in age- matched, untreated
APP+PS1 transgenic mice, and no significant difference was found
in the level of Ab staining between these two groups (6g, h).
Compared to mice injected with rAAV-NEP-m, mice injected
with rAAV-NEP-n showed significantly less Ab staining in both
the hippocampus and anterior cortex (Fig. 6b, 6e), with a
significant decrease of 71% in the anterior cortex, and a significant
decrease of 64% in the hippocampus as compared to NEP-m mice
(Fig. 6g, 6h). Mice injected with NEP-s showed a significant
decrease of 66% in Ab load in the anterior cortex but no decrease
in the hippocampus as compared to NEP-m mice (Fig. 6g, 6h).
PLOS ONE | www.plosone.org

Discussion
It is now thought that a contributing factor in cases of sporadic,
late-onset Alzheimer’s disease may be a deficiency in the
catabolism of the Ab peptide by enzymes such as neprilysin
(NEP) and insulin-degrading enzyme (IDE) [3,4,5,6]. The
potential of NEP to degrade Ab in vivo was first demonstrated by
Iwata et al. [11], who injected synthetic, radio-labeled Ab into the
CA1 region of the rat hippocampus. They showed that Ab was
most significantly degraded by NEP, and that infusion of a NEP
inhibitor caused Ab to accumulate in hippocampal fractions.
Additionally, NEP- deficient mice have significant impairment in
the degradation of intracranially- injected Ab, and have significantly elevated Ab deposition [6]. Similarly, the elevated Ab load
of APP transgenic mice can be significantly reduced when these
mice are crossed with mice over-expressing NEP [10]. In humans,
it has been demonstrated that NEP mRNA, protein, and activity
levels are significantly reduced in high plaque areas, particularly
6
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Figure 4. Study 2: Ab immunostaining is observed in mice throughout both the ipsilateral hippocampus (A, B and C) and ipsilateral
anterior cortex (D, E and F). Ab staining in the hippocampus of animals that received intracranial injections of rAAV- IDE-n (B) or IDE-s (C) is
unchanged compared to staining in those animals that received injections of control vector rAAV- GFP (A). Ab staining in the anterior cortex of mice
that received intracranial injections of rAAV- IDE-n (E) or IDE-s (F) is also unchanged compared to staining in mice that received control vector rAAVGFP (D). Scale bar = 120 mm. Quantification of percent area of positive staining is shown in the hippocampus (G) and in the anterior cortex (H). No
significant differences were observed. n = 8/group.
doi:10.1371/journal.pone.0059626.g004

control brains [5,23]. Membrane-bound IDE protein levels and
activity are also significantly decreased in patients with AD as
compared to healthy controls, and this decrease is specific to the
hippocampus [24]. Studies in mice provide further evidence for
the relationship between IDE and Ab: mice homozygous for a
deletion in the IDE gene on chromosome 10 have a significant
decrease in Ab degradation within brain membrane fractions [25],
and the elevated Ab load of APP transgenic mice can be
significantly reduced when these mice are crossed with mice overexpressing IDE [10].

the hippocampus and frontal cortex, in AD brains as compared to
healthy controls [21,22].
The link between Ab and IDE was first demonstrated by
Kurochkin and Goto [9], who showed that 125I-labeled synthetic
Ab cross-linked to a single protein within cytosol fractions from rat
brain. They identified this protein as IDE, and used purified rat
IDE to efficiently degrade Ab [9]. It was subsequently shown that
human IDE is also capable of degrading Ab, and that the
degradation of Ab by IDE in cytosolic fractions from AD brains is
reduced by 50% as compared to fractions from age-matched
PLOS ONE | www.plosone.org
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Figure 5. Study 2: Congophilic staining is observed in mice throughout both ipsilateral hippocampus (A, B and C) and ipsilateral
anterior cortex (D, E and F). Congophilic staining in the hippocampus of animals that received intracranial injections of rAAV- IDE-n (B) or IDE-s (C)
is unchanged compared to staining in those animals that received injections of control vector rAAV- GFP (A). Congophilic staining in the anterior
cortex of mice that received intracranial injections of rAAV- IDE-n (E) or NEP-s (F) is also unchanged compared to staining in mice that received control
vector rAAV- GFP(D). Scale bar = 200 mm. Quantification of percent area of positive total congophilic staining is shown in G and H (hemisphere
ipsilateral to injection sites). No significant differences were found. n = 8/group.
doi:10.1371/journal.pone.0059626.g005

deposition in mice, which can be prevented by co-administration
of an HSV vector expressing NEP. Lastly, Spencer et al. [29] have
shown continued over-expression of NEP and reduction of Ab
load up to six months post injection of lenti-NEP in transgenic
APP mice. However, there have not been any similar studies
investigating the use of viral vector expression of IDE to degrade
Ab in the transgenic mouse brain.
In the present study, our goal was to further explore the effects
of Ab degrading enzyme up-regulation via injection of viral

Recently, other studies using viral vectors to introduce Abdegrading enzymes into the brains of transgenic mouse models of
Alzheimer’s disease have been performed. Marr et al. [26] have
shown that intracranial injections of lentiviral vectors expressing
NEP result in a significant reduction in Ab load in 12–20 month
old APP mice, and Iwata et al. [27] have achieved similar results
using rAAV expression of NEP in the brains of young and old APP
mice. More recently, Hong et al. [28] have shown that administration of a lentiviral vector expressing APP results in rapid Ab
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Figure 6. Study 3: Ab immunostaining is observed in mice throughout both the hippocampus (A, B and C) and anterior cortex (D, E
and F). Ab staining in the hippocampus of animals that received intracranial injections of rAAV- NEP-n (B) is reduced compared to staining in those
animals that received injections of control vector rAAV- NEP-m (A). Ab staining in the anterior cortex of mice that received intracranial injections of
rAAV- NEP-n (E) or NEP-s (F) is also reduced compared to staining in mice that received control vector rAAV- NEP-m (D). Scale bar = 50 mm.
Quantification of percent area of positive total Ab staining is shown in and H. The (*) indicates significance compared to NEP-m mice with p,0.05; the
( ) indicates significance compared to Tg control mice with p,0.05. The (#) indicates significance compared to NEP-m mice with p,0.01. Tg control
(n = 9), NEP-n (n = 4), NEP-m (n = 7), NEP-s (n = 6).
doi:10.1371/journal.pone.0059626.g006
‘

synthesized after viral transduction both in vivo (Fig. 1) and in
transfected HEK293 cells. The NEP-s enzyme was successfully
secreted from cells, as evidenced by its detection in the cell media
fractions from NEP-s transfected HEK293 cells (results not
shown). Also, the media fractions from rAAV-NEP-s transfected
cells had a significantly higher specific NEP activity than the media
fractions from either rAAV-NEP-m or rAAV-NEP-n transfected
cells [15]. Viral constructs were expressed in vivo; six weeks after
intracranial injection, expression of rAAV-NEP-m and rAAVNEP-n was widespread throughout the hippocampus and anterior

vectors. More specifically, there were three major issues that we
have attempted to address. First, the above mentioned studies on
this topic incorporated the native form of the NEP gene into their
respective viral vectors [26,27,28,29]. The native NEP enzyme is a
transmembrane protein, which may have limited access to
extracellular amyloid deposits. To potentially expand the distribution of the NEP enzyme and improve Ab clearance, we created
a construct encoding a secreted form of the enzyme by removing
the transmembrane domain and adding a secretion signal
sequence to the N-terminus of the native NEP gene. HA was
PLOS ONE | www.plosone.org
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Figure 7. Study 3: Congophilic staining is observed in mice throughout both the hippocampus (A, B and C) and anterior cortex (D, E
and F). Congophilic staining in the hippocampus of animals that received intracranial injections of rAAV- NEP-n (B) is reduced compared to staining
in those animals that received injections of control vector rAAV- NEP-m (A). Congophilic staining in the anterior cortex of mice that received
intracranial injections of rAAV- NEP-n (E) or NEP-s (F) is also reduced compared to staining in mice that received control vector rAAV- NEP-m (D). Scale
bar = 50 mm. Quantification of percent area of positive total Ab staining is shown in G and H. The (*) indicates significance compared to NEP-m mice
with p,0.05, the ( ) indicates significance compared to Tg control mice with p,0.05, and the (u) indicates significance compared to Tg control mice
with p,0.01. Tg control (n = 9), NEP-n (n = 4), NEP-m (n = 7), NEP-s (n = 6).
doi:10.1371/journal.pone.0059626.g007
‘

capable of degrading amyloid over a larger brain area than the
native NEP enzyme.
The Ab observed reductions on the contralateral side of the
mouse brain may result from one of two reasons. Firstly, the NEP
protein is axonally transported to synapses [27] and thus may
travel via commissural projections to the contralateral side
contributing to increased NEP activity and Ab reduction.
Alternatively, the AAV constructs may be retrogradely transported
via nerve terminals at the injection site to cells on the contralateral
side where the NEP would be expressed. We suspect the first
alternative is most likely, as we have not previously seen significant

cerebral cortex, although the anti-HA immunostaining in NEP-s
mice appeared less intense. This may be due to the diffusion of the
NEP-s into the neuropil. Both enzymes resulted in a significant
reduction in Ab and Congophilic plaque burden in the ipsilateral
hippocampus and anterior cortex as compared to NEP-m treated
mice. However, NEP-s may exert effects over a larger volume,
because NEP-s treated mice experienced slightly more reduction
in Ab and Congo red staining in the contralateral hippocampus
and anterior cortex than did NEP-n mice. These results show that
the ability of NEP-s to reduce amyloid load is comparable to that
of the native NEP enzyme, and suggests that NEP-s may indeed be
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Figure 8. Study 3: CD68 (A-C) and CD45 (D-F) immunostaining is observed throughout the hippocampus of study mice. In the
hippocampus, no significant differences are observed in the amount of total CD68 staining between the NEP-n, NEP-s, and NEP-m groups, but CD45
staining in NEP-s treated mice is greater than CD45 staining in NEP-m treated mice. Scale bar = 50 mm. Panels G and H present ANOVA analysis of the
ratio of CD68 to congophilic staining, and of the ratio of quantitated CD45 to congophilic staining, respectively, in the hippocampus of study mice.
The (*) indicates significance compared to NEP-m mice with p,0.05, and the ( ) indicates significance compared to Tg control mice with p,0.05 or
p,0.01 (u).Tg control (n = 9), NEP-n (n = 4), NEP-m (n = 7), NEP-s (n = 6).
doi:10.1371/journal.pone.0059626.g008
‘

from both IDE-n and IDE-s transfected HEK293 cells displayed
IDE enzyme activity and similar levels of expression on Western
blot. However, the specific activity in IDE-n lysates was
approximately 18-fold higher than that in IDE-s lysates. The
reduced activity of the IDE-s enzyme may be due to the truncation
that was performed on the native IDE gene. Song et al. have
shown that deletion of C-terminal residues 1002–1019 of the IDE
gene creates instability in the normal dimer interface of the
enzyme, causing it to become a monomer. This resulted in a
reduction of the rate of Ab degradation to 0.25–1% the rate of
wild type IDE [30]. In vivo, expression of both IDE-n and IDE-s
were observed in the ipsilateral anterior cortex and hippocampus

neuronal cell body transduction on the contralateral side only
diffuse staining when examining with the reporter GFP [18].
Another protease capable of degrading Ab is IDE. Overexpression of IDE resulted in reduction in Ab deposition [10],
while knockout of IDE was associated with increased Ab
deposition in transgenic mouse models [25]. However, there have
not been any studies using viral transduction methods to increase
IDE expression to date. In this study, we further examined the
potential therapeutic effects of the IDE enzyme by incorporating
both native IDE (IDE-n) and a truncated, secreted form of IDE
(IDE-s) into rAAV vectors for intracranial injection into APP+PS1
mice. Results of an in vitro activity analysis showed that lysates
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in a pattern similar to that presented for Study 1. However, neither
enzyme resulted in a reduction of either Ab or Congophilic plaque
load in either brain region. These results suggest that the rAAVIDE-n and rAAV-IDE-s constructs do not have the same
therapeutic potential as the rAAV-NEP-n and rAAV-NEP-s
constructs.
Lastly, we examined the long-term over expression of rAAVNEP-s compared to rAAV-NEP-n. We observed that both NEP-n
and NEP-s continued to be expressed in the APP+PS1 mouse
brain nine months post-injection, as evidenced by anti-HA
immunostaining. Furthermore, mice that received NEP-n experienced a significant decrease in Ab and Congophilic plaques in
each brain region as compared to both groups of control mice.
Compared to NEP-n mice, mice that received NEP-s did
experience equally significant reductions in Ab and Congophilic
plaques in the anterior cortex, but did not show the same degree of
amyloid reduction in the hippocampus. In this brain region, NEPs mice showed a significant reduction in Congophilic plaques as
compared to the Tg control mice, but Ab was not significantly
reduced as compared to either control group.
Finally, we examined microglial activation after viral transduction. Previous studies have shown that injection of LPS causes a
reduction in Ab that is concurrent with microglial activation, and
can be blocked with dexamethasone [31,32]. Nine months after
intracranial injection of either rAAV-NEP-n or rAAV-NEP-s, we
investigated the level of immune activation by staining for CD45
and CD68, both markers of activated microglial cells. We
observed that the ratio of CD45:Congo and CD68:Congo red
were both significantly elevated in the hippocampus of rAAVNEP-n treated animals as compared to untreated Tg and rAAV-

NEP-m treated controls. Neither the CD45:Congo red nor the
CD68:Congo red ratio was significantly elevated in rAAV-NEP-s
treated animals. These results suggest that the native NEP enzyme,
but not the secreted version, was able to sensitize the microglial
reaction towards the Congophilic deposits, possibly facilitating
their removal. For uncertain reasons the NEP-s appeared less
capable of this activity. This may be why the NEP-n was as
effective as the NEP-s in the 9 month study.
In conclusion, we further explored the efficacy of viral vector
mediated introduction of Ab-degrading enzymes at reducing the
amyloid load in transgenic mice in three major ways. First, we
created a rAAV vectors containing a truncated, secreted form of
the NEP gene, rAAV-NEP-s, to potentially expand the brain area
over which Ab is degraded. Second, we created a rAAV vector
containing IDE to evaluate whether this enzyme produces results
comparable to rAAV-NEP. Third, we conducted a long-term
study in which rAAV-NEP was allowed to remain in the mouse
brain for nine months. Our results for these studies indicate that
while rAAV-IDE does not have the same therapeutic potential as
rAAV-NEP, rAAV-NEP-s and NEP-n are effective at reducing
amyloid loads, and both of these vectors continue to have
significant effects nine months post-injection. As such, they may be
considered reasonable candidates for gene therapy trials in AD.
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